Clodronate-nintedanib-loaded exosome–liposome hybridization enhances the liver fibrosis therapy by inhibiting Kupffer cell activity
Keqin Ji, Mingrui Fan, Dong Huang, Lingna Sun, Bingqin Li, Ruoting Xu, Jiajing Zhang, Xuan Shao, Yanzuo Chen
Abstract
-induced fibrosis mouse model by inhibiting the proliferation of fibroblasts. Furthermore, the inhibited Kupffer cells regenerated within 10 days after dosage withdrawal. Unlike carrier-free NIN treatment, CLD/NIN@LIEV induced a marked decrease in liver enzymes, indicating improved safety and anti-fibrosis efficacy. These results indicate its great potential for treatment with the combined anti-fibrosis agent and Kupffer cell inhibition strategies to enhance the liver fibrosis therapy.
Topics & Concepts
NintedanibPhagocytosisExosomeKupffer cellChemistryLiposomeFibrosisLiver fibrosisCancer researchInternalizationCell biologyMicrovesiclesCellImmunologyPathologyMedicineBiologyIdiopathic pulmonary fibrosisBiochemistryInternal medicineLungmicroRNAGeneLiver physiology and pathologyPhagocytosis and Immune RegulationImmunotherapy and Immune Responses